Antimicrobial peptides: A new alternative for the treatment of aspergillosis

Rev Mal Respir. 2024 Mar 7:S0761-8425(24)00141-4. doi: 10.1016/j.rmr.2024.02.011. Online ahead of print.ABSTRACTAspergillus fumigatus is the predominant fungal species causing pulmonary aspergillosis. The present-day anti-aspergillosis arsenal is limited, with a number of molecules occasioning severe side effects (amphotericin B) or provoking significant drug interactions (azole derivatives). Moreover, the recent emergence of azole-resistant A. fumigatus strains is a cause for concern. In this context, antimicrobial peptides (AMPs) are emerging as a promising therapeutic approach and alternative or complement to conventional antifungals.PMID:38458868 | DOI:10.1016/j.rmr.2024.02.011
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Authors: Source Type: research